Figure 1: Structure of influenza B polymerase. Figure 2: Promoter 3′-end binding and PB1 β-ribbon flexibility. Figure 3: Model for replication initiation and elongation by influenza polymerase.

Their goal: to stay a step ahead of bird flu, a group of avian-adapted viruses that experts have long worried could evolve to spread easily among humans and potentially set off the next pandemic.

WEST LAFAYETTE, Ind. — Eradivir, a preclinical biotech company, has developed a patent-pending antiviral therapeutic that reduces lung viral loads of advanced-stage influenza in preclinical studies ...